06/07/2022

L’application TousAnticovid a une “utilité marginale” dans la lutte contre la pandémie


La Cnil pointe du doigt l'utilité "marginale" de la fonctionnalité de contact tracing dans l'application TousAntiCovid. Un comble, étant donné qu'il s'agit de son objectif principal : tracer les chaînes de contamination pour les casser. En réalité, l'application est aujourd'hui principalement utilisée pour stocker le pass sanitaire.

Lire l'article complet sur : www.usine-digitale.fr

05/07/2022

Lessons from COVID: EU’s vaccine passport proves digital health’s potential | Euronews

Following the success of its vaccine passport, the Digital COVID Certificate, the EU is investing more into digital health with the European Health Data Space. EU Commissioner Stella Kyriakides speaks to Smart Health about how it will change our lives. #SmartHealth

Lire l'article complet sur : www.euronews.com

09/06/2022

COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records

Our analyses illustrate the wide spectrum of disease trajectories as shown by differences

in incidence, survival, and clinical pathways. We have provided a modular analytical

framework that can be used to monitor the impact of the pandemic and generate evidence

of clinical and policy relevance using multiple EHR sources.

Lire l'article complet sur : www.thelancet.com

09/06/2022

Racial and ethnic differences in COVID-19 outcomes: a call to action

The COVID-19 pandemic has demanded a huge effort to identify the risks associated

with poor outcomes. The focus has been particularly relevant in patients with immune-mediated

inflammatory diseases and those on therapies that suppress the immune system. Small

early observational studies looked worrisome, but as data from larger studies became

available a consistent picture became evident. Demographic risk factors such as age

and comorbidity are really the salient factors, with some risk from underlying disease

and a few specific therapeutic agents, such as rituximab.

Lire l'article complet sur : www.thelancet.com

Aller au contenu principal